GSK3B and amyotrophic lateral sclerosis: In the FUS [1–359]-transgenic mouse model of ALS, DBT-treated mice displayed improvements in physiological outcomes, motor function, and muscle atrophy compared to vehicle, and the treatment normalized brain levels of GSK-3β, GSK-3β mRNA, and IL-1β mRNA in the spinal cord [17].